Subscribe: pubmed: Thromb Haemost[jour]
http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=0vRu_d0bpxUnGUrBWsFKzyVbC2pmlEJfowY_EGcPO_o
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
brain tumours  brain  haemost jan  jan authors  patients  platelet  pmid pubmed  related articles  thromb haemost  vte        
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: pubmed: Thromb Haemost[jour]

pubmed: Thromb Haemost[jour]



NCBI: db=pubmed; Term=Thromb Haemost[jour]



 



Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation.
Related Articles

Susceptibility to chronic social stress increases plaque progression, vulnerability and platelet activation.

Thromb Haemost. 2017 Jan 12;:

Authors: Giannarelli C, Rodriguez DT, Zafar MU, Christoffel D, Vialou V, Peña C, Badimon A, Hodes GF, Mury P, Rabkin J, Alique M, Villa G, Argmann C, Nestler EJ, Russo SJ, Badimon JJ

PMID: 28078352 [PubMed - as supplied by publisher]




Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
Related Articles

Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.

Thromb Haemost. 2017 Jan 12;:

Authors: Chai-Adisaksopha C, Linkins LA, ALKindi SY, Cheah M, Crowther MA, Iorio A

Abstract
Venous thromboembolism (VTE) is one of the most common complications in patients with brain tumours. There is limited data available in the literature on VTE treatment in these patients. We conducted a matched retrospective cohort study of patients with primary or metastatic brain cancer who were diagnosed with cancer-associated VTE. Patients were selected after a retrospective chart review of consecutive patients who were diagnosed with cancer-associated VTE between January 2010 and January 2014 at the Juravinski Thrombosis Clinic, Hamilton, Canada. Controls were age- and gender-matched patients with cancer-associated VTE from the same cohort, but without known brain tumours. A total of 364 patients with cancer-associated VTE were included (182 with primary or metastatic brain tumours and 182 controls). The median follow-up duration was 6.7 (interquartile range 2.5-15.8) months. The incidence rate of recurrent VTE was 11.0 per 100 patient-years (95 % CI; 6.7-17.9) in patients with brain tumours and 13.5 per 100 patient-years (95 % CI; 9.3-19.7) in non-brain tumour group. The incidence of major bleeding was 8.6 per 100 (95 % CI; 4.8-14.7) patient-years in patients with brain tumours versus 5.0 per 100 patient-years (95 % CI; 2.8-9.2) in controls. Rate of intracranial bleeding was higher in brain tumour patients (4.4 % vs 0 %, p-value=0.004). In summary, rates of recurrent VTE and major bleeding were not significantly different in patients with cancer-associated VTE in the setting of primary or metastatic brain tumours compared those without known brain tumours. However, greater numbers of intracranial bleeds were observed in patients with brain tumours.

PMID: 28078351 [PubMed - as supplied by publisher]




Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.
Related Articles

Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials.

Thromb Haemost. 2017 Jan 12;:

Authors: Dentali F, Mumoli N, Prisco D, Fontanella A, Di Minno MN

Abstract
Compelling evidence suggests that the risk of pulmonary embolism (PE) and deep-vein thrombosis (DVT) persists after hospital discharge in acutely-ill medical patients. However, no studies consistently supported the routine use of extended-duration thromboprophylaxis (ET) in this setting. We performed a meta-analysis to assess efficacy and safety of ET in acutely-ill medical patients. Efficacy outcome was defined by the prevention of symptomatic DVT, PE, venous thromboembolism (VTE) and VTE-related mortality. Safety outcome was the occurrence of major bleeding (MB) and fatal bleeding (FB). Pooled odds ratios (ORs) and 95 % confidence intervals (95 %CI) were calculated for each outcome using a random effects model. Four RCTs for a total of 28,105 acutely-ill medical patients were included. ET was associated with a significantly lower risk of DVT (0.3 % vs 0.6 %, OR 0.504, 95 %CI: 0.287-0.885) and VTE (0.5 % vs 1.0 %, OR: 0.544, 95 %CI: 0.297-0.997); a non-significantly lower risk of PE (0.3 % vs 0.4 %, OR 0.633, 95 %CI: 0.388-1.034) and of VTE-related mortality (0.2 % vs 0.3 %, OR 0.687, 95 %CI: 0.445-1.059) and with a significantly higher risk of MB (0.8 % vs 0.4 %, OR 2.095, 95 %CI: 1.333-3.295). No difference in FB was found (0.06 % vs 0.03 %, OR 1.79, 95 %CI: 0.384-8.325). The risk benefit analysis showed that the NNT for DVT was 339, for VTE was 239, and the NNH for MB was 247. Results of our meta-analyses focused on clinical important outcomes did not support a general use of antithrombotic prophylaxis beyond the period of hospitalization in acutely-ill medical patients.

PMID: 28078350 [PubMed - as supplied by publisher]




Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: A comment.
Related Articles

Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: A comment.

Thromb Haemost. 2017 Jan 12;:

Authors: Rosendaal FR, Cannegieter SC

PMID: 28078349 [PubMed - as supplied by publisher]




The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with G-protein coupled receptor 15.
Related Articles

The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with G-protein coupled receptor 15.

Thromb Haemost. 2017 Jan 12;:

Authors: Pan B, Wang X, Kojima S, Nishioka C, Yokoyama A, Honda G, Xu K, Ikezoe T

Abstract
Thrombomodulin (TM) exerts cytoprotection via the fifth region of epidermal growth factor (EGF)-like domain of TM (TME5) by interacting with G-protein coupled receptor 15 (GPR15) expressed on cell surface of vascular endothelial cells. TM is also implied to mediate anti-inflammatory functions by unknown mechanism. By applying a lipopolysaccharide (LPS)-induced murine sepsis model, we assessed the role of TME5 in septic inflammation and coagulation. We found that TME5 treatment protected mice in association with ameliorating inflammation and coagulopathy in LPS-induced sepsis. Further study confirmed that TME5 bound GPR15 in vitro. Knock out of GPR15 abolished protective role of TME5 in sepsis model. GPR15 mediated anti-inflammatory function of TME5 through suppression of phosphorylation of IκBα, nuclear translocation of NF-κB and release of pro-inflammatory cytokines in macrophages (Macs). Knock out of GPR15 resulted in dysregulated immune response of Macs, characterised by excessive expression of pro-inflammatory genes and failing to limit immune response. This study indicates that TME5 exerts anti-inflammatory function through inhibition of NF-κB in a GPR15-dependent manner. The use of TME5 may be a potential therapeutic option for treatment of sepsis.

PMID: 28078348 [PubMed - as supplied by publisher]




Alterations of the platelet proteome in type I Glanzmann thrombasthenia caused by different homozygous delG frameshift mutations in ITGA2B.
Related Articles

Alterations of the platelet proteome in type I Glanzmann thrombasthenia caused by different homozygous delG frameshift mutations in ITGA2B.

Thromb Haemost. 2017 Jan 12;:

Authors: Loroch S, Trabold K, Gambaryan S, Reiß C, Schwierczek K, Fleming I, Sickmann A, Behnisch W, Zieger B, Zahedi RP, Walter U, Jurk K

Abstract
Glanzmann thrombasthenia (GT) is one of the best characterized inherited platelet function disorders but global platelet proteome has not been determined in these patients. We investigated the proteome and function of platelets from two patients with type I GT, caused by different homozygous ITGA2b mutations, from family members and unrelated controls. The global proteome of highly purified washed platelets was quantified by liquid chromatography-mass spectrometry (LC-MS) and targeted MS-methods. Platelet function was analysed by flow cytometry, light transmission aggregometry and flow-based assays. Platelets from GT patients showed less than 5 % relative levels of the integrin subunit αIIb and 5-7 % fibrinogen compared to controls. These patients demonstrated loss of αIIbβ3-dependent platelet function, but normal platelet granule secretion induced by physiological agonists. Platelets from heterozygous family members of a patient expressed 50-60 % of control αIIb levels which were sufficient for normal αIIbβ3-dependent platelet function. Studying type I GT as model disease we established quantitative LC-MS to detect and clearly distinguish normal platelets, platelets from GT heterozygotes and platelets from GT patients. Diminished levels of factor XIIIB chain, plasminogen and carboxypeptidase 2B were identified in thrombasthenic platelets. Additionally, GT platelets showed up to 2.5-fold increased levels of FcγRIIA and laminin-α4 chain. Elevated levels of platelet FcγRIIA was associated with increased CD63-surface expression after FcγRIIA-crosslinking in one GT-patient which might present a compensatory mechanism of platelet activation in GT. We demonstrate that quantitative LC-MS based proteomics is suitable to validate known but also to identify previously unknown protein level changes of dysfunctional platelets.

PMID: 28078347 [PubMed - as supplied by publisher]




A happy and prosperous New Year 2017 with "Thrombosis and Haemostasis" …. and our 60(th) Anniversary!
Related Articles

A happy and prosperous New Year 2017 with "Thrombosis and Haemostasis" …. and our 60(th) Anniversary!

Thromb Haemost. 2017 Jan 05;117(1):1-2

Authors: Lip GY, Weber C

PMID: 28066853 [PubMed - in process]




Editors' Choice 2016 papers in Thrombosis and Haemostasis.
Related Articles

Editors' Choice 2016 papers in Thrombosis and Haemostasis.

Thromb Haemost. 2017 Jan 05;117(1):204-206

Authors: Weber C, Lip GY

PMID: 28066852 [PubMed - in process]